Highlights

  • Ryoncil is approved in the United States for a defined paediatric graft-versus-host disease indication.
  • FY26 net loss was US$57.5 million, while year-end cash was US$103 million.
  • Operating cash outflow totalled US$43.8 million for FY26.
  • Adult clinical development and other programmes remain subject to trial and regulatory outcomes.

Mesoblast Limited (ASX:MSB) develops allogeneic cellular medicines for inflammatory diseases. Its 2026 operations combined commercial Supply of Ryoncil in the United States with clinical development across additional indications. Ryoncil treats steroid-refractory acute graft-versus-host disease in children younger than 12, a serious complication following donor stem-cell transplantation.

FY26 results and funding

Mesoblast (ASX:MSB) reported a FY26 net loss of US$57.5 million, a reduction of 44% from the prior year. Gross Profit excluding Amortisation was reported at US$110 million. These measures describe different aspects of performance: gross profit reflects product Economics before several corporate and development expenses, whereas the net loss includes a broader cost base. The company remained loss-making despite the commencement of commercial revenue.

Net cash used in Operating Activities was US$43.8 million during FY26. Second-half operating cash use was US$13.4 million, compared with US$50 million in the comparable prior-year period. The lower second-half outflow is relevant to liquidity, but does not establish that cash generation will remain positive or that spending requirements have ended. Cash at the financial year-end stood at US$103 million.

Mesoblast (ASX:MSB) also reported a US$125 million Credit Facility carrying an 8% interest rate, with no scheduled principal amortisation for five years. The facility provides access to Debt funding but introduces interest expense and eventual repayment or refinancing obligations. Funding needs will depend on commercial receipts, clinical spending and the timing of future regulatory decisions.

Ryoncil launch and commercial concentration

Ryoncil is used for a relatively uncommon paediatric condition, so orders can be influenced by the number of eligible patients treated at specialist hospitals and the timing of institutional purchases. Mesoblast (ASX:MSB) stated that Revenue exceeded its initial projections and expressed an expectation of growth in the following fiscal year.

Commercial progress should be assessed alongside product concentration. Ryoncil currently supplies the principal approved-product opportunity described in the company update, while sales depend on access to treatment centres, reimbursement arrangements and reliable product availability. A change in ordering patterns at a small number of centres can affect individual reporting periods.

Clinical programmes and milestones

Mesoblast (ASX:MSB) is studying Ryoncil in adults with severe steroid-refractory acute graft-versus-host disease. The described trial involves 180 patients and compares an existing treatment alone against that treatment combined with Ryoncil. The company anticipated an interim assessment in the fourth quarter of 2027 after approximately 100 enrolments. This remains a planned assessment, not an established efficacy result.

Its rexlemestrocel-L programme includes work in heart failure and chronic low back pain. Management indicated that Phase III back-pain results were expected in the second half of calendar 2027, with any subsequent approval dependent on clinical and regulatory review. The company also described regulatory progress for a planned paediatric Duchenne muscular dystrophy study.

Risks and FY27 considerations

The main uncertainties for Mesoblast (ASX:MSB) are commercial adoption in a small patient population, the pace of hospital orders, Manufacturing reliability, trial recruitment and clinical outcomes. Interest costs and ongoing research expenditure also affect the cash balance. Management expects operating cash use to decline in FY27, but did not identify a quarter in which the Business would become cash-flow positive.

Key Insights

Mesoblast (ASX:MSB) entered FY27 with an approved paediatric product, ongoing clinical studies and a reported FY26 operating cash outflow. The central distinction is between commercial revenue already recorded and future indications that still require successful trials and regulatory decisions.